Excellent cytoskeletal marker in developing neurons, astrocytes and fibroblasts!
- 100 µl
- Chicken, total IgY fraction
- Rat, Mouse, Human
- WB 1:1,000 IF 1:500
- Molecular Reference:
- ~50 kDa
- Cite This Antibody:
- PhosphoSolutions Cat# 2105-VIM, RRID:AB_2492283
The antigen is a recombinant human Vimentin purified from E. coli.
The antibody is Total IgY fraction.
Vimentin is the major protein subunit of the 10nm or intermediate filaments (IFs) found in many kinds of mesenchymal and epithelial cells as well as developing neuronal and astrocytic precursor cells in the CNS. Vimentin is thought to be critically involved in lymphocyte adhesion and transmigration (Nieminen M et al. 2006). Copolymers are frequently formed between vimentin and other IFs, such as GFAP (in many kinds of astrocytes), desmin (in muscle cells) and neurofilament proteins (in developing neurons). Antibodies to vimentin are useful in studies of stem cells and generally to reveal the filamentous cytoskeleton. Recent studies suggest that vimentin affects prostate cancer cells motility and invasiveness (Zhao et al. 2008).
Liquid. Contains 10 mM sodium azide.
For long term storage –20° C is recommended in undiluted aliquots. Stable at –20° C for at least 1 year. Avoid freeze/thaw cycles.
Product Specific References
Kirane, A., Ludwig, K. F., Sorrelle, N., Haaland, G., Sandal, T., Ranaweera, R., Toombs, J.E., Wang, M., Dineen, S.P., Micklem, D., Delliger, M.T., Lorens, J.B., & Brekken, R. A. (2015). Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research, canres-2887. PMID: 26206560
Ostapoff, K. T., Cenik, B. K., Wang, M., Ye, R., Xu, X., Nugent, D., Hagopian, M.M., Topalovski, M., Rivera, L.B., Carroll, K.D., & Brekken, R. A. (2014). Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer research, 74(18), 4996-5007. PMID: 25060520
Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA (2012) Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res. Sep 15;18(18):5031-42. PMID: 22829202
Kirane A, Toombs JE, Larsen JE, Ostapoff K, Meshaw KR, Zaknoen S, Brekken RA, Burrows FJ (2012) Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis 33(9):1639-46. PMID: 22678114